Riccardo R.
- Country
- Italy
- Department
- UOC Chirurgia Gastroenterologica Ospedale San Raffaele
Research Overview
- Phase III Multicenter Trial of PIPAC with Fluorouracil, Docetaxel, and Nivolumab in Oligometastatic Peritoneal Gastric Adenocarcinoma
- WINDOW-OF-OPPORTUNITY UMBRELLA PLATFORM TRIAL OF SHORT-COURSE PRE-OPERATIVE OR NEOADJUVANT TARGETED TREATMENT IN PATIENTS WITH MOLECULARLY SELECTED AND RESECTABLE PRIMARY COLORECTAL CANCER: THE UNICORN STUDY
Data & Insights
Has run more than one trial at 1 of 25 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating gastric adenocarcinoma and colorectal cancer, with particular emphasis on innovative therapeutic approaches for patients with advanced disease stages.
- Peritoneal Metastases Management
- Targeted Preoperative Treatments
- Multimodal Therapy Approaches
Their work encompasses the evaluation of novel treatment combinations including pressurized intraperitoneal aerosol chemotherapy and targeted therapeutic interventions.
Surgical Oncology
The investigator focuses on advancing surgical interventions for gastrointestinal cancers, particularly in the context of cytoreductive surgery and multimodal treatment strategies.
- Resectable Primary Cancers
- Surgical Response Assessment
- Pathological Response Evaluation
Their expertise includes evaluating pathological complete response and major response rates following preoperative treatments.
Precision Medicine
The investigator explores molecularly selected treatment approaches in gastrointestinal cancers, implementing personalized therapeutic strategies.
- Molecular Patient Selection
- Targeted Therapy Applications
- Treatment Response Analysis
Their research includes evaluation of short-course preoperative targeted treatments in specific patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.